11.1 Early-Onset vs. Late-Onset Sepsis & Maternal GBS Management

11.1 Early-Onset vs. Late-Onset Sepsis & Maternal GBS Management

Neonatal sepsis remains one of the leading causes of morbidity and mortality in both term and preterm infants. Due to the quantitative and qualitative immaturity of the neonatal immune system, localized infections can rapidly progress to fulminant bacteremia, septic shock, disseminated intravascular coagulation (DIC), and meningitis within hours of onset.

1. Neonatal Immune System Immaturity & Vulnerability

The neonatal immune system is uniquely primed for immune tolerance in utero to avoid maternal-fetal immunological conflict, leaving the newborn highly vulnerable to invasive bacterial, viral, and fungal pathogens after birth.

Quantitative and Qualitative Immune Deficits

• Innate Immunity & Phagocytic Dysfunction:

  • Impaired Neutrophil (PMN) Chemotaxis & Phagocytosis: Neonatal polymorphonuclear neutrophils exhibit rigid cellular membranes, reduced deformability, and decreased expression of surface adhesion molecules (e.g., selectins and beta-2 integrins [CD11b/CD18]). This impairs leukocyte rolling, endothelial adhesion, and diapedesis into infected tissues.
  • Exhaustion of Bone Marrow Storage Pools: Unlike adults, neonates—particularly preterm infants—have a severely limited bone marrow neutrophil storage pool. Under conditions of overwhelming bacterial sepsis, marrow stores are rapidly exhausted within 24 to 48 hours, precipitating severe peripheral neutropenia (Absolute Neutrophil Count [ANC] < 1,750/mcL), which is a cardinal indicator of poor clinical prognosis.
  • Deficient Complement System: Circulating concentrations of classical, alternative, and lectin pathway complement proteins (including C1q, C3, C4, C5, and factor B) are reduced to approximately 50% of adult levels in term infants and even lower in preterm infants. This results in impaired pathogen opsonization, reduced generation of chemotactic factors (C3a, C5a), and blunted Membrane Attack Complex (MAC / C5b-9) lytic activity.
  • Monocyte and Macrophage Inefficiency: Macrophages exhibit blunted production of pro-inflammatory cytokines (e.g., Tumor Necrosis Factor-alpha [TNF-α], Interleukin-1 beta [IL-1β], and Interferon-gamma [IFN-γ]) and deficient intracellular killing of encapsulated organisms.

• Adaptive Immunity & Immunoglobulin Kinetics:

  • Absence of Endogenous IgM and IgA: Immunoglobulin M (IgM) and Secretory Immunoglobulin A (sIgA) are large, pentameric/dimeric molecules that do not cross the syncytiotrophoblast layer of the placenta. Because fetal immunoglobulin synthesis is minimal under normal conditions, newborns have near-zero endogenous IgM and IgA at birth. Elevated cord blood IgM (>20 mg/dL) signifies intrauterine fetal antigenic exposure, commonly seen in congenital TORCH infections.
  • Transplacental Maternal IgG Transport: Maternal Immunoglobulin G (IgG) is the only antibody class actively transported across the placenta. This active transport is mediated by the neonatal Fc receptor (FcRn) located on the syncytiotrophoblast:
    • Transport begins at approximately 13 to 16 weeks gestation at low baseline rates.
    • Transport accelerates exponentially during the third trimester (≥32 weeks gestation), with more than 50% of total maternal IgG transferred between 34 and 40 weeks.
    • By 38 to 40 weeks gestation, term infants have circulating IgG concentrations that equal or exceed maternal serum levels (100–110% of maternal titers).
    • Preterm infants born at <32 weeks gestation miss this critical third-trimester surge, leaving them profoundly hypogammaglobulinemic and dependent entirely on limited innate defense mechanisms.
  • T-Cell Skewing: Neonatal T cells are predominantly antigenically naive (CD45RA+) and skewed toward a Th2 (anti-inflammatory) phenotype rather than a Th1 (cell-mediated cytotoxic) phenotype, blunting the production of IFN-γ and IL-2 necessary to eradicate intracellular pathogens like Listeria monocytogenes.

2. Early-Onset Sepsis (EOS) vs. Late-Onset Sepsis (LOS)

Neonatal sepsis is categorized clinically and epidemiologically by the timing of onset, route of transmission, microbial etiology, and presenting clinical characteristics.

Comparative Overview: EOS vs. LOS

3. Maternal Group B Streptococcus (GBS) Screening & Intrapartum Antibiotic Prophylaxis (IAP)

Group B Streptococcus (Streptococcus agalactiae) is an encapsulated Gram-positive diplococcus that colonizes the gastrointestinal and lower genital tracts of 15% to 30% of pregnant women. Without intervention, approximately 50% of infants born to colonized mothers become colonized, and 1% to 2% develop invasive early-onset disease (bacteremia, pneumonia, or meningitis).

CDC and ACOG Clinical Screening Guidelines

• Universal Screening Window: All pregnant individuals must undergo universal rectovaginal screening for GBS at 36 0/7 to 37 6/7 weeks of gestation, unless a previous indication for IAP has already been established during the current pregnancy.
• Collection Technique: A single swab is inserted into the lower vagina (without speculum) and through the anal sphincter into the rectum to maximize bacterial recovery.
• Duration of Validity: A negative GBS screening culture is considered clinically valid for 5 weeks. If delivery does not occur within 5 weeks, re-testing is indicated.

Definitive Indications for Intrapartum Antibiotic Prophylaxis (IAP)

Intrapartum antimicrobial prophylaxis is indicated during active labor or upon rupture of membranes for any woman meeting ANY of the following criteria:

1. Positive GBS screening culture (rectovaginal swab) during the current pregnancy at 36 0/7 to 37 6/7 weeks.
2. Documented GBS bacteriuria or UTI at any colony count (e.g., ≥10,000 CFU/mL or lower) during ANY trimester of the current pregnancy (signifies high genital tract bacterial load).
3. History of a previous infant with invasive GBS disease (GBS sepsis, pneumonia, or meningitis in a prior pregnancy).
4. Unknown GBS status at the onset of labor (culture not performed or results unavailable) with ANY of the following intrapartum risk factors:
   • Preterm labor at < 37 0/7 weeks of gestation.
   • Prolonged Rupture of Membranes (ROM ≥ 18 hours).
   • Maternal intrapartum fever (temperature ≥ 38.0°C / 100.4°F).
   • Intrapartum rapid molecular test (NAAT / PCR) positive for GBS.

Conditions Where IAP Is NOT Indicated

• Planned cesarean delivery performed before labor onset and before rupture of amniotic membranes, regardless of maternal GBS colonization status or gestational age.
• Negative GBS screening culture performed within the prior 5 weeks, even in the presence of intrapartum risk factors (unless clinical chorioamnionitis develops, which warrants broad-spectrum maternal therapy).

Evidence-Based IAP Regimens & Penicillin Allergy Stratification

Critical Timing Rule: Adequate IAP is defined as the administration of IV Penicillin G, IV Ampicillin, or IV Cefazolin ≥ 4 hours prior to delivery. Clindamycin and Vancomycin do not have established minimum time thresholds to be considered "adequate" for infant management algorithms; infants born to mothers receiving clindamycin/vancomycin are managed similarly to infants with inadequate IAP.

4. Sepsis Risk Stratification: Kaiser Calculator vs. Categorical Approach

Modern neonatal care balances aggressive sepsis detection with minimizing unnecessary maternal-infant separation, invasive blood draws, and broad-spectrum antibiotic exposure.

The Kaiser Sepsis Risk Calculator (SRC)

Developed by Kaiser Permanente and endorsed by the AAP, the neonatal Sepsis Risk Calculator is a validated multivariate prediction model for infants born at ≥ 34 0/7 weeks of gestation:

• Maternal Predictive Variables: Baseline incidence of EOS in the population, highest maternal intrapartum temperature, duration of rupture of membranes, maternal GBS colonization status, and the specific type and timing of intrapartum antibiotics administered.
• Infant Examination Classification:
  • Clinical Illness: Persistent respiratory distress, apnea, hemodynamic instability, encephalopathy/seizures, or need for continuous mechanical/CPAP support.
  • Equivocal Presentation: Transient tachypnea, mild grunting/retractions resolving within 2 hours, isolated mild hypothermia, or single temperature spike.
  • Well-Appearing: Completely normal physical examination, stable vitals, active feeding.
• Clinical Utility: The SRC generates an objective sepsis risk score (per 1,000 live births) and provides actionable guidance: routine clinical monitoring, serial vital signs, blood culture, or immediate empiric antibiotics. Implementing the SRC has safely reduced neonatal blood culture draws by 50–60% and empiric antibiotic exposure by 40–50% without increasing adverse sepsis outcomes.

5. Diagnostic Laboratory Evaluation of Neonatal Sepsis

When neonatal sepsis is suspected, a standardized diagnostic workup must be initiated promptly before the first dose of antimicrobial therapy.

Core Diagnostic Modalities

1. Blood Culture (The Gold Standard):

   • Inoculation Volume: A minimum volume of 0.5 to 1.0 mL of blood must be inoculated into a pediatric blood culture bottle. Inoculating low volumes (<0.5 mL) leads to false-negative cultures because neonatal bacteremia is frequently low-colony-count (1 to 10 colony-forming units [CFU] per mL of blood).
   • Site Preparation: Meticulous aseptic skin preparation with alcoholic chlorhexidine (or povidone-iodine in VLBW) with complete drying before venipuncture to prevent contamination with skin flora (S. epidermidis).
   • Draw from a fresh peripheral venipuncture; avoid drawing through indwelling vascular lines unless evaluating catheter-related sepsis.

2. Complete Blood Count (CBC) with Manual Differential:

   • Total White Blood Cell Count (WBC): Leukocytosis (>25,000–30,000/mcL) is physiologically common in the first 24 hours of life. Leukopenia (WBC < 5,000/mcL) has a significantly higher positive predictive value and specificity for invasive bacterial sepsis.
   • Absolute Neutrophil Count (ANC): Absolute neutropenia (< 1,750/mcL in the first 72 hours; < 1,000/mcL thereafter) strongly correlates with severe bacterial sepsis and rapid bone marrow exhaustion.
   • Immature-to-Total (I:T) Neutrophil Ratio: $\text{I:T Ratio} = \frac{\text{Immature Neutrophils (Bands + Metamyelocytes + Myelocytes)}}{\text{Total Neutrophils (Segmented Neutrophils + Immature Neutrophils)}}$
     • Normal baseline I:T ratio is < 0.16 to 0.20 in term infants.
     • An I:T ratio > 0.20 to 0.25 indicates a severe "left shift" and active granulopoiesis in response to bacterial infection.
   • Platelet Count: Thrombocytopenia (platelet count < 100,000/mcL) is a non-specific late marker that reflects endothelial damage, platelet consumption, and microvascular thrombosis associated with severe sepsis or DIC.

3. C-Reactive Protein (CRP):

   • CRP is an acute-phase reactant synthesized by hepatocytes in response to interleukin-6 (IL-6).
   • Kinetic Profile: CRP levels rise slowly, becoming detectable at 6 to 12 hours post-insult and peaking at 24 to 48 hours.
   • Clinical Decision Making: A single normal CRP at birth has very low sensitivity and CANNOT rule out early-onset sepsis. However, serial normal CRPs (<10 mg/L or <1.0 mg/dL) measured at 24 and 48 hours of life have a 99% Negative Predictive Value (NPV) for excluding bacterial infection, providing objective support to discontinue empiric antibiotics.

4. Lumbar Puncture (LP) & CSF Analysis:

   • Indications: Mandatory in any infant with a positive blood culture, clinical signs of meningitis (seizures, bulging fontanel, extreme lethargy, temperature instability refractory to therapy), or progressive clinical deterioration on antibiotics.
   • Diagnostic Parameters for Neonatal Bacterial Meningitis:
     • Elevated White Blood Cell count in CSF (>20–30 WBCs/mcL, with neutrophil predominance).
     • Elevated CSF Protein (>100–150 mg/dL in term; >150–200 mg/dL in preterm).
     • Decreased CSF Glucose (< 50% of simultaneous blood glucose or absolute CSF glucose < 30–40 mg/dL).
     • Positive CSF Gram stain and bacterial culture.

6. Empiric Antimicrobial Therapy & Treatment Durations

Empiric Regimens

• Early-Onset Sepsis (EOS):
  • IV Ampicillin (150–200 mg/kg/day divided every 8–12 hours) + IV Gentamicin (4–5 mg/kg once daily extended-interval dosing).
  • Coverage: Ampicillin provides bactericidal coverage against Listeria monocytogenes, GBS, Enterococcus, and susceptible E. coli. Gentamicin provides concentration-dependent synergistic killing of Gram-negative enteric bacilli (E. coli, Klebsiella) and Enterococci.
• Late-Onset Sepsis (LOS):
  • IV Vancomycin (10–15 mg/kg/dose with interval adjusted for PMA) + IV Gentamicin (or IV Cefepime if pseudomonal or multidrug-resistant Gram-negative infection is suspected).
  • Coverage: Vancomycin provides bactericidal coverage against Methicillin-Resistant Staphylococcus aureus (MRSA) and biofilm-forming Coagulase-Negative Staphylococci (S. epidermidis).

Treatment Durations & Antimicrobial Time-Out

• Rule-Out Sepsis: Stop antibiotics at 36 to 48 hours if blood cultures show no bacterial growth, serial CRPs remain normal, and the neonate is clinically well.
• Confirmed Uncomplicated Bacteremia: 7 to 10 days of targeted IV antimicrobial therapy.
• Confirmed GBS Meningitis: Minimum 14 days of IV Penicillin G or Ampicillin.
• Confirmed Gram-Negative Meningitis (E. coli): Minimum 21 days (or at least 14 days after the first sterile repeat CSF culture).